Enable Injections, Inc.

Enable Injections, Inc. is a healthcare innovation company based in Cincinnati, Ohio, founded in 2010. The company specializes in developing and manufacturing advanced wearable drug delivery systems. Its flagship product, the enFuse® on-body delivery platform, is a mechanical, hands-free injector designed to deliver large volumes of pharmaceutical and biologic therapeutics subcutaneously. This system allows patients to self-administer treatments that typically require intravenous infusion, enhancing convenience and comfort. The enFuse system is compatible with standard drug container closures and features a discreet design with a hidden needle that retracts automatically after use. Enable Injections operates primarily through partnerships with pharmaceutical and biotechnology companies, generating revenue from development agreements, licensing, and manufacturing. The company has notable collaborations with major firms like Sanofi, Roche, and Apellis Pharmaceuticals. In September 2023, the enFuse device received FDA approval for use with Apellis’ drug for paroxysmal nocturnal hemoglobinuria. With over $300 million raised in capital funding, Enable Injections is committed to improving patient experiences and reducing healthcare costs.

• Employees 200
• Founded 2010
• Annual Revenue $24800000
• Total Funding $345000000